Ipilimumab/nivolumab/pembrolizumabEncephalitis: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1868卷 / 1期

关键词：

D O I：

10.1007/s40278-021-00684-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：227 / 227

相关论文

共 50 条

[21] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
Reactions Weekly, 2024, 2037 (1) : 222 - 222
[22] Ipilimumab/nivolumab/pembrolizumabImmune related adverse events : 4 case reports
Reactions Weekly, 2020, 1791 (1) : 151 - 151
[23] Ipilimumab/nivolumab/pembrolizumabPneumonitis: 2 case reports
Reactions Weekly, 2022, 1917 (1) : 327 - 327
[24] Ipilimumab/nivolumab/pembrolizumabEncephalopathy: 14 case reports
Reactions Weekly, 2021, 1860 (1) : 205 - 206
[25] Ipilimumab/nivolumab/pembrolizumabTrabeculitis: 2 case reports
Reactions Weekly, 2022, 1933 (1) : 253 - 253
[26] Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports
Reactions Weekly, 2021, 1871 (1) : 216 - 216
[27] Ipilimumab/nivolumab/pembrolizumabHepatitis: 7 case reports
Reactions Weekly, 2022, 1922 (1) : 341 - 341
[28] Ipilimumab/nivolumab/pembrolizumabCardiotoxicity: 8 case reports
Reactions Weekly, 2017, 1638 (1) : 129 - 130
[29] Ipilimumab/nivolumab/pembrolizumabSarcoidosis: 2 case reports
Reactions Weekly, 2017, 1676 (1) : 176 - 176
[30] Ipilimumab/nivolumab/pembrolizumabArthralgia: 11 case reports
Reactions Weekly, 2020, 1794 (1) : 130 - 130

← 1 2 3 4 5 →